Akero Therapeutics, Inc. (NASDAQ:AKRO) Receives $82.50 Average Price Target from Analysts

Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO - Get Free Report) have received a consensus rating of "Buy" from the six brokerages that are covering the firm, Marketbeat reports. Six investment analysts have rated the stock with a buy rating. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $82.50.

Several brokerages recently weighed in on AKRO. Citigroup reduced their price target on shares of Akero Therapeutics from $80.00 to $78.00 and set a "buy" rating on the stock in a research report on Tuesday, May 13th. Bank of America lifted their price objective on shares of Akero Therapeutics from $63.00 to $64.00 and gave the stock a "buy" rating in a research note on Tuesday, May 27th.

Insider Buying and Selling at Akero Therapeutics

In other Akero Therapeutics news, CEO Andrew Cheng sold 37,837 shares of the company's stock in a transaction that occurred on Tuesday, June 10th. The stock was sold at an average price of $54.05, for a total value of $2,045,089.85. Following the sale, the chief executive officer owned 556,487 shares in the company, valued at approximately $30,078,122.35. This represents a 6.37% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Catriona Yale sold 10,000 shares of the stock in a transaction that occurred on Thursday, May 15th. The shares were sold at an average price of $39.30, for a total value of $393,000.00. Following the transaction, the insider owned 95,034 shares in the company, valued at $3,734,836.20. This trade represents a 9.52% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 232,156 shares of company stock worth $11,589,728 in the last 90 days. Corporate insiders own 7.07% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Janney Montgomery Scott LLC purchased a new position in shares of Akero Therapeutics during the 2nd quarter worth $203,000. Palumbo Wealth Management LLC purchased a new position in shares of Akero Therapeutics during the 2nd quarter worth $262,000. Voya Investment Management LLC raised its holdings in shares of Akero Therapeutics by 302.9% during the 1st quarter. Voya Investment Management LLC now owns 82,471 shares of the company's stock worth $3,338,000 after acquiring an additional 62,000 shares during the period. Rhumbline Advisers raised its holdings in shares of Akero Therapeutics by 4.7% during the 1st quarter. Rhumbline Advisers now owns 110,687 shares of the company's stock worth $4,481,000 after acquiring an additional 5,001 shares during the period. Finally, Strs Ohio purchased a new position in shares of Akero Therapeutics during the 1st quarter worth $510,000.

Akero Therapeutics Price Performance

NASDAQ:AKRO traded up $0.73 during trading hours on Monday, hitting $54.33. 983,646 shares of the stock traded hands, compared to its average volume of 1,054,600. The company has a quick ratio of 16.80, a current ratio of 16.80 and a debt-to-equity ratio of 0.03. Akero Therapeutics has a 1 year low of $21.34 and a 1 year high of $58.40. The company has a market cap of $4.33 billion, a price-to-earnings ratio of -27.86 and a beta of -0.15. The stock has a 50 day moving average price of $50.39 and a 200 day moving average price of $44.18.

Akero Therapeutics (NASDAQ:AKRO - Get Free Report) last released its quarterly earnings data on Monday, May 12th. The company reported $0.90 earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.01) by $1.91. Sell-side analysts forecast that Akero Therapeutics will post -3.99 EPS for the current fiscal year.

About Akero Therapeutics

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.